| Old Articles: <Older 8061-8070 Newer> |
|---|
 |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up.   |
The Motley Fool
November 14, 2011
Stephanie Baum |
Safeguard Scientifics: Health IT Could Grow to One-Quarter of Investments Safeguard Scientifics recognizes the increasing crossover between health-care services and IT. |
The Motley Fool
November 11, 2011
Evan Niu |
MAKO Surgical Is Breaking the Rules The company reports strong third-quarter revenue but still has yet to turn a profit. |
The Motley Fool
November 11, 2011
Sean Williams |
Aeterna Zentaris Surprises Again A quarterly profit shocks analysts and me alike. |
The Motley Fool
November 10, 2011
Keki Fatakia |
A Not-So-Dynamic Quarter for AngioDynamics The medical-equipment maker posts revenue below analyst expectations. |
The Motley Fool
November 10, 2011
Dan Caplinger |
Has Savient Pharmaceuticals Become the Perfect Stock? For Savient to get closer to perfection, it simply has to do one thing: Make Krystexxa the success story it seemed to be last year. |
The Motley Fool
November 9, 2011
Brian Orelli |
Byetta Breakup! Buying Opportunity? We all saw this coming. Amylin Pharmaceuticals and Eli Lilly decided staying together for the kids just wasn't worth it |
The Motley Fool
November 9, 2011
David Williamson |
Market Crash = Biotech Carnage Highlighting the day's health-care stories critical to investors. |
The Motley Fool
November 9, 2011
Anders Bylund |
Accretive Health's Shares Got Crushed: What You Need to Know Shares of health-care revenue management expert Accretive Health don't look all that healthy today after falling as much as 13.5% on more than triple their average trading volume. |
The Motley Fool
November 8, 2011
David Williamson |
Biotech Pops, Drops, and Break-Ups Highlighting the day's health-care stories critical to investors. |
| <Older 8061-8070 Newer> Return to current articles. |
